

Study Of Expression And Association Of Hsp90, Her2, P⁵³ and Ki-67 In Gastric And Colorectal Neoplasms In The Indian Context

Short Title: Expression Of Hsp 90, Her2, P 53 And Ki 67 In Git Tumors

Dr Sunethri Padma¹, Dr Rahul Dev Singh Rathore², Dr Shravan Kumar Odapally³, Dr Shravan Kumar Parika⁴, Dr Uday Kumar Putcha⁵

¹Associate Professor of Pathology, Gandhi medical college, Hyderabad, Telangana, India

²Consultant Pathologist, Yashoda Hospitals, Hyderabad, Telangana, India

³Dean and Professor of Pathology, RVM Medical College, Telangana, India

⁴Professor and Head of Gastroenterology, Gandhi Medical College Hyderabad, Telangana, India

⁵Senior Scientist G, National Institute of Nutrition, Hyderabad, India

Abstract: Introduction: *Gastrointestinal malignancies are on raise and there is a need for predictive and prognostic markers to study the tumor behavior. In the present study we have evaluated four most important markers in these tumors in Indian population so that drugs targeting these proteins can be included in the therapeutic regimes. We also compared the expressions with the grade and stage of the tumors. Materials and methods: The present study is an observational cross-section study. We have included neoplasms of Stomach, Colon and Rectum, 30 benign and 30 malignant neoplasms from each organ. Results: HSP 90 expression was associated with the grade and stage of all tumors except grade of colonic tumors. HER2 was associated with grade and stage of all tumors except stage of stomach and rectum. Ki67 expression was associated with grade and stage of all tumors except stage of rectal carcinoma. P53 is associated with grade and stage of all the tumors. Conclusion: Marked geographical variations have been identified in the phenotypic characters of the tumors. An understanding of the pattern of expression of prognostic and predictive markers shall be helpful in better analysis of the tumor behavior.*

Keywords: *Gastrointestinal neoplasms, HSP 90 expression, Ki67 expression, P53 expression.*

1. INTRODUCTION

Gastrointestinal neoplasms are one of the leading causes of cancer deaths world wide. In western countries, the incidence of carcinoma colon is more where as in the eastern world gastric cancer is common. In India, as per the incidence data derived from the recent report of ICMR/NCDIR-NCRP (2012-2016), gastric cancer is one of the commonest gastrointestinal malignancy besides cancers of Lung, mouth and esophagus. Recent statistics show that the

overall incidence of cancer has increased in recent years. Several prognostic and predictive markers related to the gastrointestinal neoplasms are being identified and novel chemotherapeutic drugs are formulated targeting these markers. Human epidermal growth factor 2 (HER 2), Heat shock protein 90(HSP 90), P53 and Ki-67 are few such important markers and drugs targeting these molecules are being included in the latest therapeutic regimens. Several studies have earlier looked to relate the expression of these markers to the staging, treatment response and survival of the patients with gastrointestinal malignancies in various population groups. All the studies reported have a wide range of varied inferences. Hence, there is a need to standardize the data by conducting studies in small population groups and derive data pertaining to that geographical area. In the present study we have analyzed the expression of all these four markers in carcinoma Stomach, Colon and Rectum in a tertiary care centre in south India.

2. MATERIALS AND METHODS

The present study is an observational cross-section study conducted in the department of pathology, Gandhi hospital, Hyderabad. Ethical clearance was obtained from Institutional Ethical Committee, Gandhi Medical College and informed consent was taken from the patients. We have included neoplasms of Stomach, Colon and Rectum in our study as these are the commonest tumors of gastrointestinal tract. Both endoscopic biopsies and resected samples were included in the study. Normal mucosa was used as control. Cases included 30 benign and 30 malignant neoplasms each from stomach, colon and rectum. The specimens were fixed in 10% buffered neutral formalin. The biopsies were processed in-toto. From the resected specimens, the tumor area was identified and tissue from that area was processed. The tissue selected was processed by the routine technique. The tissue blocks were cut for 4 micron thick sections and were stained with Hematoxylin and eosin stains. Later these slides were examined and sections for Immunohistochemistry were selected and later stained with antibodies to HSP 90, HER2, Ki 67 and P53. Immunohistochemical staining was done using peroxidase-anti-peroxidase method according to the standard protocol and Primary antibody (HSP90, HER2, Ki67 and P53) was from Dako. Positive immunoreaction is characterized by dark brown color of the targeted protein. The scoring was done by the following standard protocols: HSP 90 – score 0 <5% of positivity (Negative), 1+ 5% - 20%, 2+ 20% - 50% and 3+ >50% cells, HER 2 – Score 0 No reactivity or membranous reactivity in <10%, 1+ Faint/barely perceptible membranous reactivity in >10% of tumor cells; cells are reactive only in part of their membrane (Negative), 2+ Weak to moderate complete, basolateral, or lateral membranous reactivity in >10% of tumor cells (Equivocal), 3+ Strong complete, basolateral or lateral membranous reactivity in >10% of tumor cells (Positive) (Ruschoff et al), Ki 67 – Score 0 <5% positive cells, 1+ 6% – 25% positive cells, 2+ 26% - 75% positive cells, 3+ >75% positive cells, P53- Score 0 <5% positive cells, 1+ 6% – 25% positive cells, 2+ 26% - 75% positive cells, 3+ >75% positive cells. The evaluation of the expression of the markers was done by two pathologists independently. The expression of these markers was correlated with the histologic grade and stage of the tumor (According to WHO classification of the Tumors, 5th Edition). The tumors were categorized into 4 stages, T1 to T4 stages (WHO classification of the Tumors, 5th Edition). The results were compiled and

statistically evaluated using Pearson chi-square test, SPSS 23rd version .P value was calculated with significance less than 0.05.

3. RESULTS:

A total of 210 samples were included in the study which included Controls as well as Test samples of three sites in the gastrointestinal system- Stomach, Colon and Rectum. For each site 10 controls (Normal Tissues), 30 Benign and 30 Malignant tumors were studied.

STOMACH:

In our study, we had three types of benign neoplasms in stomach. Majority of them were Gastric Hyperplastic polyps (24cases) comprising 80% of the benign tumors. The expression of all the four markers was studied in these neoplasms. HSP 90 expression was negative in majority of the benign neoplasms (26 cases, 87%).4 cases(13%) showed +1 positivity .Her 2 was negative in 23 cases (77%) of the benign neoplasms.1+ score positivity was seen in 7 benign hyperplastic polyps of the stomach.Ki 67 and P53 were negative in all the benign neoplasms of the stomach. The age of the patients with carcinoma stomach ranged from 38 years to 68 years with a mean of 51.96 years. Majority of the patients were males with male:Female ratio being 6:1.Among 30 malignant cases,29 cases were microscopically diagnosed as Adenocarcinoma NOS and 1 case was diagnosed as Neuroendocrine carcinoma. Only One case of Adenocarcinoma was Poorly cohesive Signet Ring Cell carcinoma and rest of all the tumors were Tubular type. We have excluded neuroendocrine carcinoma and signet ring cell carcinoma from the grading. Out of the 28 cases ,16 were well differentiated(57%),8 were moderately differentiated(28%) and 4 were poorly differentiated(15%)..T1 stage had 7 cases (23.5%), T2 15 cases (50%),T3 had 8 cases(26.5% and there were no cases in T4 stage. HSP 90 expression was positive in 21 cases (70%) and negative in the remaining 9 cases(30%).Score 1 was seen in 11 cases, score 2 in 9 and score 3 in 1 case. Amongst well differentiated tumors, 5 showed score 0 ,7 cases 1+,4 cases 2+ .In moderately differentiated tumors,3 showed score 0, 2 cases1+,3 cases2+ and none of them showed 3+ score. In poorly differentiated tumors, all the tumors showed positive staining with 1 case 1+ score, 2 cases 2+ and 1 case +3 score. These results were statistically correlated and P value was found to be Significant (P value 0.035).The expression of this marker was also correlated with the staging of these tumors. Stage T1 had 7 cases,T2 had 15cases,T3 had 8 cases. In our study there was no case in T4 stage. The scoring of HSP 90 increased with the stage of the tumor. P value was Significant, <0.05 (P value-0.017).HER 2 was positive in 18 cases(60%) and negative in 12 cases(40%).7 cases(23.3%) showed Score 1+,8 cases(27%) showed score +2 and 3 cases(10%) showed 3+ score. Out of 16 cases of well differentiated carcinoma,7 cases had score 0,5 cases +1,and 4 cases 2+.No cases showed +3.Out of 8 cases of moderately differentiated carcinoma ,4 cases score 0,2 cases 1+ and 2 cases showed +2 score. Majority of the poorly differentiated carcinoma showed score 3+ .P value was found significant, <0.05 (P value 0.001). We also correlated the expression of the marker with stage of the tumor and P value was Not significant (P= 0.07).There was no association between the expression of the marker and stage of the tumor in Gastric

Carcinoma.Ki-67 was positive in all the cases of carcinoma Stomach.8 cases (27%) showed Score 1+, 19 cases (63%) showed score 2+ and 3 cases (10%) showed score 3+.The expression of Ki-67 was studied in correlation with the grade and stage of the tumor. Out of 16 cases of Well differentiated carcinoma,6 showed 1+ and 10 score 3+.Out of 8 cases of moderately differentiated cases,1 showed 1+ and 7 showed 2+.Out of 4 cases of poorly differentiated ,1 case showed 2+ and 3 showed 3+ score. P value was calculated and was found significant (P value = <0.001). The association of Ki-67 with the stage of the tumor was statistically analyzed and P value was found to be significant,< 0.05(P value=0.003).P53 was positive in 26 cases out of 30 cases.4 cases (13%) were negative with score 0.16 cases(53%) showed score1+,8 cases(27%) showed score 2+ and 2 cases (7%) show 3+ score. The expression of this protein was studied in relation to the grade and stage of the tumor. In well differentiated tumors 3 cases were negative with score 0, 10 cases showed 1+ positivity and 3 cases showed 2+ score. Out of 8 cases of moderately differentiated cases,1 showed 1+ and 4 showed 2+and 1 showed score 3+.Out of 4 cases of poorly differentiated cases,2 showed 2+ and 2 showed 3+ score. P value was calculated and was found significant (P value = <0.001). The expression of P53 was correlated with the staging of the tumor and was found to be significant, P< 0.05.(Table 1)

Table 1 : Expression of proteins in carcinoma stomach

Marker	Score 0	Score 1+	Score 2+	Score 3+
HSP 90	9(30%)	11(36.7%)	9(30%)	1(3.3%)
HER 2	12(40%)	7(23%)	8(27%)	3(10%)
Ki-67	0	8 (27%)	19(63%)	3(10%)
P53	4(13%)	16(53%)	8(27%)	2(7%)

COLON:

In our study out of 30 Benign tumors 12 cases of tubular adenoma,.16 cases of Tubulovillous adenoma. We had 2 cases of Villous adenoma. The expression of the four markers was studied in these benign neoplasms.HSP 90 was negative in all the benign neoplasms. HER 2 was negative in 27 (90%) cases and was positive with score 1+ in 3 (10%) cases. Ki 67 and P 53 were negative in all the cases.

The mean age of the patients with adenocarcinoma ranged from 32 to 64 years with a mean age of 49.33 years. Males were predominant with a ratio of 1:6.Majority of the tumors (70%) were left sided.

Hsp90 was negative in 2 of the adenocarcinomas,11 cases showed score 1+,16 cases showed 2+ and only one case showed 3+.. HER 2 expression was positive in all the malignant cases.14 cases showed score 1+ ,15 showed 2+ and only one case showed 3+.Ki 67was positive in all the cases.6 cases showed 1+,22 showed 2+ and 2 showed 3+.P 53 was negative in 2 cases ,score 1+ in 6 cases, score 2+ in 22 cases and 3+ in 2 cases. In our study, out of 30 cases, 18 were well differentiated ,9 were moderately differentiated and 3 cases were poorly

differentiated. Out of 30 tumors, 4 cases were in T1 stage, 17 were in T2, 7 in T3 and only 2 cases in T4 stage.

In well differentiated tumors, negative expression was seen in One case, 1+ in 4 cases, 2+ in 13 cases and none of the tumors expressed score 3+. In moderately differentiated tumors 1 case showed no expression, 6 showed score 1+, 2 showed score 2+ and none of the cases showed 3+ score. Out of the 3 poorly differentiated cases, 1 showed 1+ score, 1 showed 2+ and one showed 3+ score expression. The P value was Not significant ($P=0.41$) in correlation with the grade of the tumor. When the expression of this marker was correlated with the stage of the tumors, P value was found to be Significant ($p=0.001$).

All the malignant tumors expressed the HER2. None of them had score 0.14 out of 30 cases expressed score 1+, 15 cases 2+ and 1 case showed score 3+. The expression was correlated with the grade and stage of the tumor. 18 cases were well differentiated, out of which 11 showed score 1+, 7 showed 2+. Amongst 9 cases of moderately differentiated tumors, 2 showed 1+, 6 showed 2+ and 1 showed 3+ scoring. In poorly differentiated group, 2 cases showed 2+ and 1 showed 1+ scoring. P value in association with the grade of the tumor was found to be Insignificant ($P=0.149$). When correlated with the stage of the tumor P value was found Significant ($P=0.009$). Ki 67, was found to be positive in all the malignant tumors. 6 cases showed 1+, 22 showed 2+ and 2 showed 3+ score. The expression was also correlated with the stage and grade of the tumor. Out of 18 well differentiated tumors, 4 had score 1+, 13 had 2+. In moderately differentiated tumors, 2 showed score 1+, 6 showed 2+ and 1 showed 3+ score. Amongst 3 cases of poorly differentiated carcinoma, 2 showed 2+ and 1 showed 3+ scoring. The P value was found to be Significant ($P=0.001$). When the marker's expression was compared with the stage of the tumor, P value was Significant ($P=0.007$). P53 showed positivity in most of the tumors. Only 2 cases out of 30 showed negative staining. 6 showed score 1+, 20 cases showed score 2+ and 2 showed score 3+. The expression was compared with the stage and grade of the tumor. Out of 18 cases of well differentiated carcinoma only one case was negative. 5 cases showed 1+, 12 showed 2+ and none of them showed 3+ score. In moderately differentiated tumors, 1 was negative, 1 case showed 1+ and 7 cases showed 2+. In poorly differentiated carcinoma 1 case was 2+ and 2 cases showed 3+ scores. P value was found to be Significant ($P<0.001$). When the marker expression was correlated with the staging of the tumors, P value was found to be Significant ($P=0.001$). (Table 2)

RECTUM:

Out of 30 benign neoplasms, 16 were Tubular Adenoma, 4 Villous Adenoma, 10 were Tubulovillous adenoma. The expression of all the four markers was negative in all the neoplasms except one cases of Tubulovillous adenoma which showed positivity for P53. Age of the patients with carcinoma rectum ranged from 38 years to 61 years with a mean age of 50.36 years. The tumor was common in males with the Male: female ratio being 1:10. The expression of these markers was studied in these tumors. HSP 90 was positive in 20 cases and remaining 10 cases showed score 0.14 cases showed score 1+, 4 score 2+ and 2 showed score 3+. HER 2 was negative in 4 cases, 1+ in 21 cases, 2+ in 4 cases and 3+ in 1 case. Ki 67 was

positive in all cases, 20 showed 2+ and 8 showed 3+. P53 was negative in 2 cases, 1+ in 22 cases, 2+ in 6 cases and 3+ in 2 cases.

HSP 90 expression was studied in correlation with the grade and stage of the tumor. In well differentiated tumors, 10 tumors were negative, 14 cases 1+ and 2 cases 2+. In moderately differentiated tumors, 2 cases showed score 2+ and 1 case showed 3+ score. One case of poorly differentiated carcinoma showed score 3+. P value was found to be significant ($P = 0.001$) in correlation to the tumor grade. The expression of HSP 90 was statistically analysed with the stage of the tumor and P value was found to be Significant ($P < 0.001$). HER2 expression was correlated with the grade and stage of the tumor. Out of 26 cases of well differentiated tumors, 3 showed score 0, 20 showed 1+, 3 showed 2+. In moderately differentiated tumors, 1 case showed score 0, 1 case showed 1+ and only one case showed 3+. One case of poorly differentiated tumor showed 2+ score. The association of the marker with the tumor grade was found to be Significant ($P = 0.007$). When expression of the marker was correlated with the stage of the tumor P value was Not significant ($P = 0.45$). Ki67 expression was correlated with the grade and stage of the tumor. Out of 26 cases of Well differentiated tumors, 22 showed 2+ score, 4 showed 3+ score. In moderately differentiated tumors, all the 3 cases expressed score 3+. One case of poorly differentiated carcinoma expressed score 3+. P value was found to be Significant ($P = 0.002$). The expression of this marker when correlated with the stage of the tumors was found to be Not Significant ($P = 0.167$). P 53 was scored as per the criteria and the results were correlated with the grade and stage of the tumor. In well differentiated tumors, 1 case showed score 0, 20 cases showed score 1+ and 5 cases showed 2+. None of the cases showed 3+. In moderately differentiated tumors, 1 case showed score 0, 1 showed 2+ and one showed 3+ score. One case of poorly differentiated tumor showed score 3+. These results were statistically analysed and P value was Significant ($P < 0.001$). On correlation with the stage of the tumor, Significant P value ($P = 0.001$) was derived. (Table 3)(Table 4).

4. DISCUSSION:

The overall cancer burden by gastrointestinal tumors is 273982 cases by 2020 March, i.e. 19.7% of the total cancers. It is expected to raise to 19.8% by 2025 (ICMR/NCDIR-NCRP(2012-2016)). An improvised diagnostic and therapeutic modalities are warranted to curtail the increase in the incidence of these tumors. In addition, gastrointestinal tumors show a varied behavior in different patients with the same histologic type and same stage. Most of the patients present at a late stage. Hence it is necessary to include other predictive and prognostic markers in addition to the basic parameters like histologic typing and staging.

In our study, carcinoma stomach was most common in males and the mean age was 51.96 years. Arun Kumar Barad et al., has reported increased incidence of carcinoma stomach in males and the mean age in their study was 60 years [1]. They also observed the most common histologic type as Adenocarcinoma NOS (95.6%). Similar findings were reported by OT Muslim et al., where in the tumors were common in males and the commonest age group was

40-60 years [2]. In our study, carcinoma colon was common in males and mean age was 49.33 years. Huan-Cheng Changet al., in their study reported that majority of cases of carcinoma colon were under the age of 50 years [3]. RudreshaA Haleshappa et al., also had male preponderance in carcinoma colon [4]. In our study carcinoma rectum was common in men and the mean age was 50.36 years.

HSP 90:

In our study the expression of HSP 90 was associated with the grade and stage of carcinoma stomach. The expression of the marker increased with the grade of the tumor. Similar findings were reported by Jiahong Wang et al., where in the over expression of HSP90 was observed in majority (69.6%) of gastric cancers[5]. According to them HSP 90 expression was more in tumor with poor prognosis. Sabina berezowska et al., had reported contradictory results in their study where in HSP 90 expression was found to be associated with lower local tumor burden, absence of lymph node metastasis and better tumor differentiation [6]. Several researchers have proposed that inclusion of inhibitors of HSP90 would be beneficial to patients with advanced gastric cancer. Inhibition of HSP 90 expression could reduce angiogenesis and gastric cancer cell proliferation and overcome the resistance to chemotherapy [7, 8]. In our study, the expression of HSP 90 was negative in all of the benign neoplasms of colon but 96.6% of the malignant tumors showed positivity. In addition, the expression of the marker was not associated with the grade of the tumor in our study. On the contrary, in the study done by Qiu-Ran Xu1 et al., there was association between the expression of HSP 90 and grade of the tumor[9]. Similar findings were reported by Dong X, Lang L et al., Chen Y, Ran ZH et al., and Z Milicevic et al., where in the expression of HSP 90 was associated with the grade of the tumor [10,11,12]. In our study, expression of HSP 90 was found to be associated with the stage of the tumor. These findings were similar to the studies done by Qiu-Ran et al., where in, the expression of the marker increased with Dukes staging and lymphnode metastasis [12]. Z Milicevic et al., in their study, has reported that tumor progression of colonic carcinoma is associated with the expression of HSP 90. Christian Moser et al has proved that use of HSP 90 inhibitors inhibited the invasive properties of colonic cancer cells [13].

In our study, the expression of HSP 90 was seen in 66.6% of the Rectal adenocarcinomas. The expression of the marker was associated with the grade and stage of the tumor. Poorly differentiated tumors expressed more of the protein. The expression also increased with tumor invasiveness. These findings were similar to that of the study done by Qiu-Ran wi et al. Milicevic also reported similar results wherein the expression increased with tumor Stage.

HER2:

The staining pattern of HER 2 in gastric cancers has always been a debatable issue. Heterogeneity is the hall mark of these tumors. Several studies have been done in terms of Her2 testing by taking in to account inter-observer and inter-laboratory observer consensus for scoring the expression of the marker on tissue microarray. Josef Ruschoff, mafred Dietel et al., has standardized reporting of HER 2 expression in endoscopic biopsies as well as

resected specimens [14]. Similar scoring system was also proposed by Hofmann et al.[15]. The positivity of this marker in gastric cancer showed an extensive range from 2%, in the study done by Grabsch H et al., to 90%,in a study conducted by Allgaver H et al.[16,17]. In our study HER 2 was expressed in 60% of the malignant tumors. Laxmi V et al., in their study has shown that HER 2 positivity was 35.9% [18]. Raj Aditi, Rau Aarathi et al., reported HER 2 expression in 27.6% of the carcinomas where as Sekaran et al., had reported a very high positivity of 44.2 % in their study [19,20]. In our study, the expression of the protein was not associated with the grade of the tumor .The findings were similar to that of study conducted by Raj Aditi et al., where in, there was no positivity in well differentiated tumors.Studies done by Kim et al., and Marx et al., showed that majority of HER 2 positivity was seen in moderately differentiated tumors,51.8% and 60% respectively [21,22]. On the contrary in the studies done by Tateshi et al., had shown that the expression was more in well differentiated tumors compared to poorly differentiated tumors [23]. Similar findings were reported by Phillips et al., and Fisher SB et al.[24,25]. In our study, the expression of the marker increased with the stage of the tumor and there by tumor progression. Yan et al., and Chua et al., also stated that the protein expression is associated with only stage of the tumor rather than site and type of the tumor [26,27].

We have adopted same scoring system as that of gastric cancer for scoring the expression of HER 2 in colonic carcinoma.. The expression of HER2 in colonic adenocarcinoma in our study was 100% and majority of the showed score 1+.According to our knowledge ,no study has reported such high percentage of positivity. Ingold Heppner et al., have reported a very less positivity,1.6% [28]. Various studies have shown a varied positive percentage of HER 2 expression in colonic caecinoma. A maximum of 80% was reported by Kruszewski WJ et al., and a minimum of 0% was reported by Blok EJ et al [29,30] . In our study, the expression of HSP 90 was not associated with the grade of the tumor. Positivity was seen in mostly well differentiated tumors with score 1+.The finding were similar to the study done by Suma S et al [31]. Seo AN et al., in their study also showed no correlation with the differentiation of the tumor and other clinicopathological parameters [32]. In our study, Her 2 expression was associated with the stage of the tumor. Similar results were reported Ingold Heppner et al. In addition, the expression was also related to lymphnode metastasis and local growth. Zahra Heidri et al., in their study has shown no association with HER 2 expression and stage of the tumor [33]. They did not find any relationship with lymphnode metastasis and expression of the marker. In our study, only stage T3 tumors showed score 3+ expression. Suma S et al., has shown that majority of Stage B cases showed positivity in their study group. In our study, among rectal adenocarcinomas, HER 2 was expressed in 86.6% of the tumors. Similar findings were reported by Marshall J et al [34]. According to Mohammed E Salem [35], amongst the tumors of large intestine, tumors of rectum expressed more of Her 2 compared to other tumors. In study conducted by ConradiLc et al., the percentage of expression of HER 2 in rectal cancers was 26.7% [36]. In our study, there was association between the grade of the tumor and expression of HER 2.Conradi LC et al., also showed association of the grade of the tumor with expression of the protein. Rameez Hasan et al., has reported that the marker was expressed more in well differentiated tumors than moderately and poorly differentiated

tumors [37]. According to Ji-Lin Li et al., there was correlation between the expression of the marker and grading of the tumor [38]. In our study, the stage of the tumor is not associated with the expression of the marker. Where as Richman SD et al., and Valtorta E et al., have reported the association of HER2 with the stage of the tumor [39,40].

P53:

In our study, P53 was expressed in 86.6% of the Gastric adenocarcinomas. The expression was nuclear in all the tumors. Young- EunJoo et al., in their study also had P53 positivity in all the gastric tumors and was nuclear positivity [41]. They have described lot of heterogenisity in gastric tumors but in our study the staining was homogenous. Shashikanth et al., has reported P 53 positivity in 72% of the gastric cancers in their study [42]. Ygomyo et al., has reported 65% positivity of P53 in gastric carcinomas [43]. In our study, expression of P53 was associated with the histologic grade of the tumor as well as stage of the tumor. It was similar to the study done by Tushar Hiralal et al., and Teiichiro Honda et al., where in the expression of the marker was associated with the histologic grade of gastric carcinoma as well as TNM staging of the tumor [44,45]. In our study, P53 expression was negative in all the benign neoplasms of colon. In malignant neoplasms, 90% of the tumors showed P53 positivity with majority of the adenocarcinomas showing score 2+. several studies have given variable positive percentage of P53 in colonic adenocarcinoma. In the study done by Kavitha Mardi et al., P53 was expressed in 70% of the tumors [46]. Ghavam-Nasiri et al., had reported 40% positivity of P53 in colonic adenocarcinomas in their study [47]. In our study, we have observed that the expression of P53 was associated with the tumor grade and stage of colonic adenocarcinomas which was similar to the study done by Hye Seung Han et al. [48]. On the contrary, P53 expression was not associated with grade and stage of the tumor in the study done by Kavitha Mardi et al. [46]. In our study, 96.6% of the rectal adenocarcinomas showed P53 positivity. Márcia Teresinha Jurach et al., has reported 41% positivity of P53 in rectal adenocarcinomas [49]. In our study, the expression of P53 was associated with the grade and stage of the rectal adenocarcinomas. Marcia Teresinha Jurach has observed that there was no correlation between the expression of the marker with the stage and grade of the tumor. Mohammad-Reza Ghavam-Nasiri MD et al., in their study, has found that there was no association between the expression of the marker and stage or grade of the rectal carcinomas.

Ki 67:

Ki67 was negative in all the benign neoplasms of Stomach but was positive in all the adenocarcinoma. It also showed correlation with the stage and grade of the tumor. Similar findings were reported in the study done by H.Amrani et al., wherein Ki 67 expression was associated with the grade and stage of the tumor[50]. In our study, colorectal adenocarcinoma expressed Ki 67 and it was associated with the grade tumor. O Fluge et al., has reported similar findings where in they have observed association of the marker with the grade and stage of the tumor [51]. But in our study we didn't find any association between the marker and stage of rectal adenocarcinoma.

5. CONCLUSION:

Gastrointestinal tumors are one of the most extensively studied tumors. Marked geographical variations have been identified in the phenotypic characters of the tumors and understanding of the pattern of expression of prognostic and predictive markers shall be helpful in better analysis of the tumor behavior. Numerous studies done throughout the world had given varied results regarding the expression of these particular markers and this makes it necessary to standardize the data in sub-population groups to overcome this geographical variation. Also newer therapeutic drugs have evolved which would target these proteins and inhibit the tumor cell proliferation and survival. Hence, study of the expression of these markers in gastrointestinal tumors would help in identifying the patients who would benefit from using these drugs in therapeutic regimes. In the present study we have studied only the expressed proteins in the tumor cells but further evaluation by studying the genetic expression of these markers would give extensive information on the genes of these markers and also accentuate the value of these markers in their role as predictive and prognostic markers.

6. REFERENCES:

- [1] Arun Kumar Barad¹, Sanjeet Kumar Mandal², Hiriyur S Harsha³, Birkumar M. Sharma¹, Th Sudhirchandra Sing Gastric cancer-A clinicopathological study in a tertiary care centre of North-eastern Indian Journal of Gastrointestinal oncology Vol 5, No 2 (April 2014)
- [2] OT Muslim The distribution of gastric malignancies in AL-Diwaniyah province-Iraq, a retrospective study Mon, 28 Oct 2019 in International Journal of Research in Pharmaceutical Sciences
- [3] 3.Huan-Cheng Chang,^{1,2} Jorng-Tzong Horng,³ Wen-Chu Lin,³ Hsin-Wen Lai,⁴ Cheng-Wei Chang,⁵ and Tzu-An Chen Evaluation of the Appropriate Age Range of Colorectal Cancer Screening Based on the Changing Epidemiology in the Past 20 Years in Taiwan International Scholarly research Notices Volume 2012
- [4] 4.Rudresha AHaleshappa, SuparnaAjitRao, SunnyGarg, CLakshmaiah Kuntegowdanahalli, Govinda Babu Kanakasetty, and Lokanatha Dasappa Is Colorectal Cancer in Young (<40 Years) Different from those in the Elderly (>40 Years): Experience from a Regional Care Center Indian J Med Paediatr Oncol. 2017 Oct-Dec; 38(4): 466–470.
- [5] 5. Jiahong Wang, Shuzhong cui et al High expression of Heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer .PLOS April 2013 vol 8, issue 4
- [6] 6.

- [7] Lee KH, Lee JH, Han SW, IM SA, Kim TY et al (2011) Antitumor activity of nvp-auy922, a novel Heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteosomal degradation of client proteins *Cancer Sci* 102;1388-1395
- [8] Lang SA, Klein D, Moser C, Gaumann A, Glockzin G et al (2007) Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularisation in vivo *Mol cancer Ther* 6:1123-1132).
- [9] Expression of HSP90 and HIF-1 in human colorectal cancer tissue and its significance Qiu-Ran Xu¹, Xin Liu², Ying-Min Yao¹, Qing-Guang Liu^{1*} *Asian Pacific Journal of Tropical Medicine* 2014 Available online 20 September 2014 doi: 10.1016/S1995-7645(14)60123-1)
- [10] Dong X, Lang L, Yu WJ. HSP90 and HSP70 expression in colorectal cancer and its biological behavior relationship. *Chin J General Surg* 2011; 20(10): 1120-1122.
- [11] Chen Y, Ran ZH, Chen X, Xiao SD. Expression of heat shock protein 70 and 90 and their relationships with biological behaviors of colon cancer. *J World Chin Digest Mag* 2012; 14(33): 3201-3205
- [12] Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression Z Milicevic¹, D Bogojevic, M Mihailovic, M Petrovic, Z Krivokapic *Int J Oncol* . 2008 Jun; 32 (6) :1169-78.
- [13] Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors *in vivo*
- [14] Christian Moser, Sven A. Lang, Silvia Kainz, Andreas Gaumann, Stefan Fichtner-Feigl, Gudrun E. Koehl, Hans J. Schlitt, Edward K. Geissler and Oliver Stoeltzing **DOI:** 10.1158/1535-7163.MCT-07-0410 Published November 2007)
- [15] HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing Josef Rüschoff¹, Manfred Dietel, Gustavo Baretton, Susanne Arbogast, Axel Walch, Geneviève Monges, Marie-Pierre Chenard, Frédérique Penault-Llorca, Iris Nagelmeier, Werner Schlake, H Höfler, H HKreipe *Virchows Arch* 2010 Sep;457(3):299-307.)
- [16] Assessment of a HER2 scoring system for gastric cancer: results from a validation study. M Hofmann¹, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel *Histopathology*. 2008 Jun;52(7):797-805.)
- [17] Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. *Cell Oncol*. 2010;32:57–65.

- [18] Allgayer H, Babic R, Gruetzner KU, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. *J Clin Oncol*. 2000;18:2201–2209
- [19] Laxmi V, Valluru VR, Madhavi J, Valluru N (2014) Role of HER 2 Neu in Gastric carcinomas – 3 year study in a medical college hospital *Ind J Appl Res* 4(11):47-50).
- [20] Raj Aditi, Rau Aarathi, Rudramurthy Pradeep, Lokanatha Hemalatha, C. Akshatha, and Kumar Amar HER2 Expression in Gastric Adenocarcinoma—a Study in a Tertiary Care Centre in South India *Indian J Surg Oncol*. 2016 Mar; 7(1): 18–24.
- [21] Sekaran A, Kandagaddala RS, Darisetty S, Lakhtakia S, Ayyagari S, Rao GV et al (2012) HER2 expression in gastric cancers in Indian population- an immunohistochemistry and fluorescence insitu hybridization study *Indian Journal of Gastroenterol* 31(3):106).
- [22] Kim MA, Jung EJ, Lee HF, Jeon YK, Yang HK (2007) Evaluation of HER 2 gene status in gastric carcinomas using Immunohistochemistry, fluorescence in situ hybridization and real time quantitative polymerase chain reaction. *Hum Pathol* 38(9):1386-9
- [23] Marx AH, Tharun I, Muth J, Dancan AM, Simon R, Yekebas E et al (2009) HER2 amplification is highly homogenous in gastric cancer *Hum Pathol* 40(6):769-77)
- [24] Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological significance of c-erbB2 protein expression in human gastric carcinoma. *J Surg Oncol*. 1992;49: 209–12.
- [25] Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. *Dis Esophagus*. 2013;26: 299–304.
- [26] Fisher SB, Fisher KE, Squires MH, 3rd, et al. HER2 in resected gastric cancer: is there prognostic value? *J Surg Oncol*. 2014;109 (2):61–6. doi: 10.1002/jso.23456
- [27] Shi-Yan Yan, Ying Hu, Jian-Gao Fan, Guo-Quan Tao, Yong-Ming Lu, Xu Cai, Bao-Hua Yu, Yi-Qun Du. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. *World J Gastroenterol*. 2011;17(11):1501–1506.
- [28] Terence C Chua¹, Neil D Merrett Clinicopathologic factors associated with HER 2 positive gastric cancer and its impact on survival outcomes-A systematic review *Int J Cancer* 2012 Jun 15 ;130(12):2845-56.
- [29] Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. *Br J Cancer*. 2014;111(10):1977–84
- [30] Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zielinski J, Szajewski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. *Dis Markers*. 2010;29(5):207–12. doi: 10.3233/DMA-2010- 0742. [PubMed: 21206005].

- [31] Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. *Clin Med Insights Oncol.* 2013;7:41–51.
- [32] HER2/neu Expression in Colorectal Cancers Suma S , Shameem K Ummerali2 *International Journal of Contemporary Medical Research Volume 4 | Issue 6 | June 2017 | ICV (2015): 77.83).*
- [33] Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. *PLoS One.* 2014;9(5). e98528
- [34] Zahra Heidari,1,2 Hamidreza Mahmoudzadeh-Sagheb,1,2 Mehdi Jahantigh,3 and EnamAlhag Immunohistochemical Expression of Ki67 and HER2 in Colorectal Cancer Compared to Adenomatous and Normal Samples *International Journal of Cancer Management* 10(11);e12252,2017
- [35] Marshall J, Lenz H-J, Xiu J. et al. Molecular variances between rectal and left-sided colon cancers. *J Clin Oncol* 2017; 35: (suppl 4S; abstr 522
- [36] Mohamed E. Salem,^{1,*} Benjamin A. Weinberg,^{1,*} Joanne Xiu,² Wafik S. El-Deiry,³ Jimmy J. Hwang,⁴ Zoran Gatalica,² Philip A. Philip,⁵ Anthony F. Shields,⁵ Heinz-Josef Lenz,⁶ and John L. Marshall Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers *Oncotarget.* 2017 Oct 17; 8(49): 86356–86368.
- [37] Conradi LC, Styczen H, Sprenger T, Wolff HA, Rödel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Rüschoff J, Liersch T Frequency of HER-2 positivity in rectal cancer and prognosis *J Surg Pathol.* 2013 Apr; 37(4):522-31
- [38] Rameez Hassan, Deepti Bhatt, Shahbaz Khan, Vasiuddin Khan, Amit Kumar Verma, Prahalad Singh Bharti, Afzal Anees & Kapil Dev Frequency of I655V SNP of HER-2/neu in colorectal cancer: a study from India *3 Biotech* volume 9, Article number: 11 (2019)
- [39] Ji-Lin Li, Shu-Han Lin, Hong-Qiu Chen, Li-Sheng Liang, Xian-Wei Mo, HaoLai, Jie Zhang, Jing Xu, Bing-Qian Gao Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis *BMC Clinical Pathology* volume 19, Article number: 3 (2019)
- [40] Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. *J Pathol* 2016;238(4):562–70.)

- [41] Valtorta E, Martino C, Sartore-Bianchi A, Penault-Llorca F, Viale G, Risio M, Ruge M, Grigioni W, Bencardino K, Lonardi S, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.* 2015;28(11):1481–91.)
- [42] Young-EunJoo Ik-Joo Chung, Young-Kyu Park, Yang-Seok Koh, Jae-Hyuk Lee, Chang-Hwan Park,[†] Wan-Sik Lee,[†] Hyun-Soo Kim, Sung-Kyu Choi,[†] Jong-Sun Rew,[†] Chang-Soo Park, and Sei-Jong Kim Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer *J Korean Med Sci.* 2006 Oct; 21(5): 871–876.
- [43] Shashikant C.U.Patne, VB Abhilash,² Vinod Kumar Dixit,³ Richa Katiyar,⁴ Sandip Kumar,⁵ and Gyan Prakash Singh . Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 (HER2) and p53 in Gastric Adenocarcinoma: A Pilot Study from Northern India *J Clin Diagn Res.* 2017 May; 11(5): EC43–EC45.
- [44] Y Gomyo , M Ikeda, M Osaki, S Tatebe, S Tsujitani, M Ikeguchi, N Kaibara, H Ito Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma *Cancer* 1997 Jun 1;79(11):2067-72
- [45] SurvivalTushar HiralalSankalecha, Sudhir Jagdish Gupta, Nitin Rangrao Gaikwad, Suresh NarayanraoUghade Correlation of P53 Expression with Various Clinicopathological Parameters of Gastric Carcinoma and Its Relationship with Survival *journal of gastroenterology and hepatology research* Vol 6 No 3 (2017)
- [46] 45. Teiichiro Honda¹, Gen Tamura, Yasushi Endoh, Satoshi Nishizuka, Sumio Kawata, Teiichi Motoyama Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach *Jpn J Clin Oncol.* 2005 Oct;35 (10):580-6.
- [47] 46. Kavita Mardi, Manika Sharma, Meena Bhardwaj, Manju Rao p53 expression in colorectal carcinomas and its correlation with clinicopathological parameters *Clinical Cancer Year : 2017 | Volume : 6 | Issue : 1 | Page : 26-29*
- [48] 47. Ghavam-Nasiri MR, Razaee E, Ghafarzadegan K, Seilanian-Toosi M, Malekifard H. Expression of p53 in colorectal carcinoma: correlation with clinicopathologic features. *Arch Iran Med.* 2007;10:38-42
- [49] 48. Hye Seung Han Young-Mee Park Tae Sook Hwang Differential expression of Bcl-2, Bcl-X_L and p53 in colorectal cancer *J Gastroenterol Hepatol.* 2006 Jul; 21(7):1108-14.
- [50] 49. Márcia Teresinha Jurach; Luise Meurer; Luis Fernando Moreira Arq Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum *Gastroenterol.* vol.43 no.1 São Paulo Jan./Mar. 2006
- [51] 50. H Armani H.J, N Marchoudi, I Sadaoui, W Mahfoud, N Elgnaouil, F Haddad, T Fechtali, H Benomar Ki 67 expression in Gastric cancer and correlation with clinic-

pathological characteristics International Journal of scientific Research Publications
Vol4, Issue 6 June 2014

- [52] 51. Ø Fluge, K Gravidal, E Carlsen, B Vonen, K Kjellevoid, S Refsum, R Lilleng, T J Eide, T B Halvorsen, K M Tveit, A P Otte, L A Akslen, and O Dahl Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis Br J Cancer. 2009 Oct 20; 101(8): 1282–1289.

Table 1: Expression of proteins in carcinoma stomach

Marker	Score 0	Score 1+	Score 2+	Score 3+
HSP 90	9(30%)	11(36.7%)	9(30%)	1(3.3%)
HER 2	12(40%)	7(23%)	8(27%)	3(10%)
Ki-67	0	8 (27%)	19(63%)	3(10%)
P53	4(13%)	16(53%)	8(27%)	2(7%)

Table 2. Expression of the markers in Malignant neoplasms of colon

MARKER	SCORE 0	+ 1	+2	+3
HSP90	02	11	16	01
HER 2	00	14	15	01
KI 67	00	06	22	02
P53	2	6	20	2

Table 3. Malignant Tumors of the Rectum

MARKER	SCORE 0	+ 1	+2	+3
HSP90	10	14	04	02
HER 2	04	21	04	01
KI 67	00	00	22	08
P53	2	20	6	2

Table 4. Significance of expression of Markers

	Hsp90 stomach grade	HER 2 stomach grade	Ki 67 Stomach grade	P53 Stomach Grade	HSP 90 stomach stage	HER 2 stomach stage	Ki67 stomach stage	P53 Stomach Stage	HSP 90 colon grade	HER 2 colon grade	Ki67 colon grade	P53 Colon Grade	HSP 90 colon stage	HER 2 Colon Stage	Ki 67 Colon Stage	P 53 Colon Stage	HSP 90 rectum grade	HER 2 rectum grade	Ki 67 rectum grade	P53 Rectum Stage	HSP 90 rectum stage	HER 2 rectum stage	Ki 67 rectum stage	P53 rectum Stage	
Chi-square																									
Chi-square, df	13.53	23.866	23.9	27.32	15.516	11.667	16.327	29.72	13.158	9.34	14.67	14.673	22.331	13.44	17.86	45.3	28.846	17.647	12.692	13.723	40.6	5.8	3.6	47.32	
P value	0.035	0.001	<0.0001	<0.0001	0.017	0.07	0.003	0.003	0.041	0.149	0.001	0.001	0.001	0.009	0.007	<0.0001	P<0.0001	0.007	0.002	0.002	P<0.0001	0.45	0.167	<0.0001	
P value summary		***			*	ns	**	**	ns	ns			***	*			***	**	**	**	***	ns	ns		
Statistically significant? (alpha<0.05)	yes	Yes	yes	yes	Yes	No	Yes	Yes	No	No	yes	yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	

FIGURE LEGEND

Figure 1. a. Villous Adenoma. b. HSP 90 expression . C. HER 2 . d. P 53 expression . e. Tubular Adenoma. f. Villous Adenoma

